A Phase I Study Of Continuous Infusion EMD 121974 In Patients With Solid Tumors

Date de début de l'étude : 1 décembre 2003

Inclusion Criteria: * Histologically confirmed solid tumor or lymphoma * Refractory to standard therapy or no standard therapy exists * Measurable or evaluable disease * No active brain metastases * Previously treated brain metastases allowed provided the patient is not currently receiving corticosteroids * Primary brain neoplasms allowed, regardless of corticosteroid use * Performance status - Karnofsky 70-100% * WBC ≥ 3,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * No life-threatening bleeding diathesis within the past 6 months * Bilirubin normal (unless due to Gilbert's syndrome) * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * No prior proven gastric or duodenal ulcer * No clinically significant gastrointestinal blood loss within the past 6 weeks * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior CNS hemorrhage * No psychiatric illness or social situation that would preclude study compliance * No other concurrent uncontrolled illness * No ongoing or active infection * No prior cilengitide (EMD 121974) * No other concurrent biologic therapy * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * No concurrent chemotherapy * See Disease Characteristics * More than 4 weeks since prior radiotherapy and recovered * No concurrent palliative radiotherapy * No other concurrent anticancer agents or therapies intended to treat the malignancy * No other concurrent investigational agents * No concurrent anticoagulation therapy that increases INR or aPTT above the normal range * Line prophylaxis allowed